Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 1527932, 8 pages
http://dx.doi.org/10.1155/2016/1527932
Clinical Study

Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes

1Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
2Pediatrics, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
3Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital Colorado, 13123 E 16th Ave, Aurora, CO 80045, USA
4Colorado School of Public Health and University of Colorado, 13001 East 17th Place, Campus Box B119, Aurora, CO 80045, USA

Received 17 June 2016; Revised 30 September 2016; Accepted 3 November 2016

Academic Editor: David Zangen

Copyright © 2016 J. L. Taylor-Cousar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. F. Foundation, Ed., Cystic Fibrosis Foundation Patient Registry, 2014, http://www.cff.org.
  2. M. Löhr, P. Goertchen, H. Nizze et al., “Cystic fibrosis associated islet changes may provide a basis for diabetes—an immunocytochemical and morphometrical study,” Virchows Archiv A Pathological Anatomy and Histopathology, vol. 414, no. 2, pp. 179–185, 1989. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Iannucci, K. Mukai, D. Johnson, and B. Burke, “Endocrine pancreas in cystic fibrosis: An Immunohistochemical Study,” Human Pathology, vol. 15, no. 3, pp. 278–284, 1984. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Moran, J. Dunitz, B. Nathan, A. Saeed, B. Holme, and W. Thomas, “Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality,” Diabetes Care, vol. 32, no. 9, pp. 1626–1631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Sui, A. K. Olivier, J. A. Klesney-Tait et al., “Ferret lung transplant: an orthotopic model of obliterative bronchiolitis,” American Journal of Transplantation, vol. 13, no. 2, pp. 467–473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Schwarzenberg, W. Thomas, T. W. Olsen et al., “Microvascular complications in cystic fibrosis-related diabetes,” Diabetes Care, vol. 30, no. 5, pp. 1056–1061, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. E. Milla, J. Billings, and A. Moran, “Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis,” Diabetes Care, vol. 28, no. 9, pp. 2141–2144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Rosenecker, R. Höfler, G. Steinkamp et al., “Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome,” European Journal of Medical Research, vol. 6, no. 8, pp. 345–350, 2001. View at Google Scholar · View at Scopus
  9. E. J. Sims, M. W. Green, and A. Mehta, “Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes,” Diabetes Care, vol. 28, no. 7, pp. 1581–1587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Chamnan, B. S. F. Shine, C. S. Haworth, D. Bilton, and A. I. Adler, “Diabetes as a determinant of mortality in cystic fibrosis,” Diabetes Care, vol. 33, no. 2, pp. 311–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Lewis, S. M. Blackman, A. Nelson et al., “Diabetes-related mortality in adults with cystic fibrosis: role of genotype and sex,” American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 2, pp. 194–200, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Moran, C. Brunzell, R. C. Cohen et al., “Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society,” Diabetes Care, vol. 33, no. 12, pp. 2697–2708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Dobson, C. D. Sheldon, and A. T. Hattersley, “Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis,” Diabetes Care, vol. 26, no. 6, pp. 1940–1941, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. P. O'Riordan, P. Hindmarsh, N. R. Hill et al., “Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: A Prospective Cohort Study,” Diabetes Care, vol. 32, no. 6, pp. 1020–1022, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Hameed, J. R. Morton, A. Jaffé et al., “Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain,” Diabetes Care, vol. 33, no. 2, pp. 221–226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Leclercq, B. Gauthier, V. Rosner et al., “Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients,” Journal of Cystic Fibrosis, vol. 13, no. 4, pp. 478–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Schiaffini, C. Brufani, B. Russo et al., “Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system,” European Journal of Endocrinology, vol. 162, no. 4, pp. 705–710, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. “Special issue: the 24th annual North American cystic fibrosis conference, Baltimore Convention Center, Baltimore, Maryland, October 21–23, 2010,” Volume 45, Issue S33 Pages 1–477, 2010.
  19. American Diabetes A, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 37, supplement 1, pp. S81–S90, 2014. View at Publisher · View at Google Scholar
  20. R. J. Miller, H. D. Tildesley, P. G. Wilcox, H. Zhang, and S. H. Kreisman, “Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study,” Canadian Respiratory Journal, vol. 15, no. 6, pp. 291–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Rolon, K. Benali, A. Munck et al., “Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy,” Acta Paediatrica, vol. 90, no. 8, pp. 860–867, 2001. View at Google Scholar · View at Scopus
  22. S. Lanng, B. Thorsteinsson, J. Nerup, and C. Koch, “Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections,” Acta Paediatrica, vol. 83, no. 8, pp. 849–853, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Rafii, K. Chapman, C. Stewart et al., “Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis,” The American Journal of Clinical Nutrition, vol. 81, no. 2, pp. 421–426, 2005. View at Google Scholar · View at Scopus
  24. K. Mohan, K. L. Israel, H. Miller, R. Grainger, M. J. Ledson, and M. J. Walshaw, “Long-term effect of insulin treatment in cystic fibrosis-related diabetes,” Respiration, vol. 76, no. 2, pp. 181–186, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. D. S. Hardin, J. Rice, M. Rice, and R. Rosenblatt, “Use of the insulin pump in treat cystic fibrosis related diabetes,” Journal of Cystic Fibrosis, vol. 8, no. 3, pp. 174–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Mozzillo, A. Franzese, G. Valerio et al., “One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements,” Pediatric Diabetes, vol. 10, no. 3, pp. 162–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Moran, P. Pekow, P. Grover et al., “Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial,” Diabetes Care, vol. 32, no. 10, pp. 1783–1788, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Schmid, K. Fink, R. W. Holl, H. Hebestreit, and M. Ballmann, “Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test,” Journal of Cystic Fibrosis, vol. 13, no. 1, pp. 80–85, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Sheikh, M. E. Putt, K. A. Forde, R. C. Rubenstein, and A. Kelly, “Elevation of one hour plasma glucose during oral glucose tolerance testing,” Pediatric Pulmonology, vol. 50, no. 10, pp. 963–969, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Brodsky, S. Dougherty, R. Makani, R. C. Rubenstein, and A. Kelly, “Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis,” Diabetes Care, vol. 34, no. 2, pp. 292–295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Dobson, A. T. Hattersley, S. Tiley, S. Elworthy, P. J. Oades, and C. D. Sheldon, “Clinical improvement in cystic fibrosis with early insulin treatment,” Archives of Disease in Childhood, vol. 87, no. 5, pp. 430–431, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Bizzarri, V. Lucidi, P. Ciampalini, S. Bella, B. Russo, and M. Cappa, “Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance,” Journal of Endocrinological Investigation, vol. 29, no. 3, pp. RC1–RC4, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Lanng, A. Hansen, B. Thorsteinsson, J. Nerup, and C. Koch, “Glucose tolerance in patients with cystic fibrosis: five year prospective study,” British Medical Journal, vol. 311, no. 7006, pp. 655–659, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Godbout, I. Hammana, S. Potvin et al., “No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes,” Diabetes and Metabolism, vol. 34, no. 6, pp. 568–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. L. A. Fox, R. W. Beck, D. Xing et al., “Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals,” Diabetes Care, vol. 33, no. 6, pp. 1297–1299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. D. Bellin, T. Laguna, J. Leschyshyn et al., “Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study,” Pediatric Diabetes, vol. 14, no. 6, pp. 417–421, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Hayes Jr., K. S. McCoy, and S. I. Sheikh, “Resolution of cystic fibrosis-related diabetes with ivacaftor therapy,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 5, pp. 590–591, 2014. View at Publisher · View at Google Scholar · View at Scopus